Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket
The surge in global cancer cases is raising serious concerns among experts. A recent study published in Monday in Cancer, a ...
Mena FN1 天
How Critical Demand For Metastatic Breast Cancer Therapies Is Producing A Multi-Billion ...
Palm Beach, FL – September 20, 2024 – Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous.
oncnursingnews1 天
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...
TMCnet1 天
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion ...
FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...
2024 ESMO｜辉瑞乳腺癌领域最新研究成果闪耀国际舞台
当地时间 2024 年 9 月 13 日至 17 日，欧洲肿瘤内科学会（ ESMO ）年会在西班牙巴塞罗那盛大召开。此次大会上，辉瑞多项关键临床试验数据亮相大会，包括哌柏西利、依西美坦以及在研新型 CDK4 ...
来凯医药-B现涨超5% 公布LAE002治疗HR+/HER2-乳腺癌Ib期临床优异数据
在2024年欧洲肿瘤内科学会 （ESMO） 大会上，来凯医药公布了其创新产品LAE002联合氟维司群（下简称“联合疗法”），用于标准治疗失败的局部晚期或转移性HR+/HER2-乳腺癌患者Ib期研究的最终数据。在18位 ...
100%无广告体验
消息面上，在2024年欧洲肿瘤内科学会 (ESMO) 大会上，来凯医药公布了其创新产品LAE002联合氟维司群（下简称“联合疗法”），用于标准治疗失败的局部晚期或转移性HR+/HER2-乳腺癌患者Ib期研究的最终数据。在18位 PIK3CA/AKT1/PTEN变异的乳腺癌患者中，中位无进展生存期 (PFS)为 7.3个月。
来凯医药-B涨超6% 公布LAE002治疗HR+/HER2-乳腺癌Ib期临床优异数据
来凯医药-B(02105)涨超6%，截至发稿，涨6.7%，报4.78港元，成交额516.23万港元。 消息面上，在2024年欧洲肿瘤内科学会(ESMO)大会上，来凯医药公布了其创新产品LAE002联合氟维司群(下简称“联合疗法”)，用于标准治疗失败的局部晚期或转移性HR+/HER2-乳腺癌患者Ib期研究的最终数据。在18位PIK3CA/AKT1/PTEN变异的乳腺癌患者中，中位无进展生存期(PFS ...
Oncolytics Biotech Reports Favorable Results For Breast Cancer Study
(RTTNews) - Clinical-stage company Oncolytics Biotech Inc. (ONCY), Thursday announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+ ...